Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data

Executive Summary

New data from Novo Nordisk supporting its GLP-1 agonist will fortify the firm's new drug applications, strengthen its position in price negotiations and boost its chances of reimbursement.


Related Content

With Novo Nordisk Dependent On GLP-1s, Even Perceived Price Pressures Can Hurt
Novo Nordisk Touts First-Line Potential For Oral Semaglutide
Novo's Semaglutide: Retinopathy Warning Unlikely To Dim Commercial Prospects
Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7
Advantage Novo As Victoza Gets CV Benefit Okay in Europe
Novo Readies For Victoza CV Benefit Claim With US FDA Panel Nod
Disappointing Bydureon EXSCEL Outcomes Data May Raise Stakes For Victoza
Cardiovascular Benefits of SGLT2 Inhibitors: A Class Effect?
Keeping Track: New Submissions In Bladder Cancer, HCV And Diabetes; Avastin Label Expands
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts